title: Hepatic disseminated tumor cells in colorectal cancer UICC stage 4 patients: prognostic implications.
abstract: Approximately 30-50% of all colorectal cancer patients with a resectable primary tumor will subsequently develop metastatic disease due to tumor cell dissemination. In the case of limited solid hepatic metastasis, resection of the primary tumor and the respective hepatic metastasis can be curative. Our aim was to evaluate the incidence of hepatic DTC in patients with solid liver metastasis and to describe their prognostic impact. Therefore, we applied a sensitive PCR-RFLP assay detecting one K-ras mutant among one million wild-type cells. Tumor tissue and liver biopsies from 32 colorectal cancer patients staged UICC 4 undergoing palliative surgery could be obtained intra-operatively and were thereupon screened for the presence of hepatic DTC. The primary tumor of 16 patients (50%) harbored a K-ras mutation and survival of K-ras positive patients was reduced as compared to K-ras negatives (P=0.039). In 8 of the patients (50%) with a K-ras mutated primary, no hepatic DTC were detected, whereas the liver of the remaining 8 patients (50%), showed a coincidence of solid liver metastasis and hepatic DTC. Median survival of patients with solid liver metastasis and hepatic DTC was decreased as compared with patients without any hepatic DTC burden (median survival 165 vs. 240 days; log-rank P=0.951). A subgroup analysis revealed that survival was significantly decreased in the case of bilobal DTC affection as compared with monolobal hepatic DTC affection (median survival 68 vs. 355 days; log-rank P=0.002). We conclude that the detection of hepatic DTC is a powerful prognostic factor. Furthermore, bilobal hepatic DTC involvement might be a contraindication for the resection of solid liver metastasis.
authors.affiliation: First Department of Internal Medicine, University Hospital Mainz, Mainz, Germany.
authors.forename: Christoph C
authors.initials: CC
authors.lastname: Schimanski
authors.forename: Ulrich
authors.initials: U
authors.lastname: Linnemann
authors.forename: Peter R
authors.initials: PR
authors.lastname: Galle
authors.forename: R
authors.initials: R
authors.lastname: Arbogast
authors.forename: Martin R
authors.initials: MR
authors.lastname: Berger
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000473:pathology*; D004247:DNA / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D011905:Genes, ras / Q000235:genetics; D006801:Humans; D008099:Liver / Q000378:metabolism; D008113:Liver Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D012150:Polymorphism, Restriction Fragment Length; D011379:Prognosis; D017422:Sequence Analysis, DNA; D013997:Time Factors
chemical_list: D004247:DNA